South Korea approves Morinaga Milk’s B. breve B-3 strain for weight management
Morinaga Milk Industry Co., Ltd. announced that its probiotic strain Bifidobacterium breve B-3 has been approved by South Korea for its efficacy in reducing body fat. This Individual Recognized Registration (No. 2023-2) validates the strain’s safety, functionality, and regulatory compliance.
Clinical Benefits of B. breve B-3
B. breve B-3, developed by Morinaga Milk, is known for its positive impact on metabolic syndrome, weight management, and overall well-being. The strain can be used as a functional ingredient for body fat reduction at a dosage of 5 billion CFU/day, backed by clinical evidence supporting its effectiveness.
Morinaga Milk’s probiotic strain B. breve B-3 gains approval in South Korea for body fat reduction. Image courtesy of Morinaga Milk Industry Co., Ltd./Business Wire.
Regulatory Compliance and Market Impact
South Korea’s regulatory environment for functional ingredients requires rigorous standards. Morinaga Milk’s B. breve B-3 meets these requirements, showcasing the company’s commitment to high-quality, science-backed health solutions. This approval is expected to enhance Morinaga Milk’s presence in South Korea’s growing probiotic market.
Recent Clinical Study Reinforces Strain’s Efficacy
A recent randomized clinical trial in South Korea confirmed the effectiveness of B. breve B-3 in reducing body fat and improving metabolic health. The study, published in Nutrients, demonstrated significant reductions in body weight, fat, waist, and hip circumference among participants taking the probiotic strain.